Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity.
Elisa LozanoPaula Sanchon-SanchezAna Morente-CarrascoLuis Miguel Chinchilla-TáboraJosé Luis MaurizPaula Fernández-PalancaJose J G MarinRocío I R MacíasPublished in: Cells (2023)
The poor prognosis of most cases of advanced cholangiocarcinoma (CCA) constitutes a severe problem in modern oncology, which is aggravated by the fact that the incidence of this liver cancer is increasing worldwide and is often diagnosed late, when surgical removal is not feasible. The difficulty of dealing with this deadly tumor is augmented by the heterogeneity of CCA subtypes and the complexity of mechanisms involved in enhanced proliferation, apoptosis avoidance, chemoresistance, invasiveness, and metastasis that characterize CCA. Among the regulatory processes implicated in developing these malignant traits, the Wnt/β-catenin pathway plays a pivotal role. Alteration of β-catenin expression and subcellular localization has been associated with worse outcomes in some CCA subtypes. This heterogeneity, which also affects cellular and in vivo models commonly used to study CCA biology and anticancer drug development, must be taken into account for CCA investigation to more accurately extrapolate basic laboratory research to the clinical situation. A better understanding of the altered Wnt/β-catenin pathway in relationship with the heterogeneous forms of CCA is mandatory for developing novel diagnostic tools and therapeutic strategies for patients suffering from this lethal disease.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- cell proliferation
- stem cells
- single cell
- chronic kidney disease
- ejection fraction
- palliative care
- risk factors
- oxidative stress
- peritoneal dialysis
- cell death
- endoplasmic reticulum stress
- metabolic syndrome
- transcription factor
- genome wide
- insulin resistance
- binding protein
- patient reported outcomes
- signaling pathway